Literature DB >> 26927969

Hypotension associated with ingestion of cannabinoids in two children with cancer.

Amanda M Li1, S Rod Rassekh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26927969      PMCID： PMC4868608          DOI： 10.1503/cmaj.150847

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  A case series of marijuana exposures in pediatric patients less than 5 years of age.

Authors:  George Sam Wang; Sandeep K Narang; Kathryn Wells; Ryan Chuang
Journal:  Child Abuse Negl       Date:  2011-08-03

3.  Quebec hospitals allow inpatient use of weed.

Authors:  Owen Dyer
Journal:  CMAJ       Date:  2014-07-14       Impact factor: 8.262

4.  Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats.

Authors:  K D Lake; B R Martin; G Kunos; K Varga
Journal:  Hypertension       Date:  1997-05       Impact factor: 10.190

5.  Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide.

Authors:  K Varga; K Lake; B R Martin; G Kunos
Journal:  Eur J Pharmacol       Date:  1995-05-24       Impact factor: 4.432

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Ingestion of cannabis: a cause of coma in children.

Authors:  A Macnab; E Anderson; L Susak
Journal:  Pediatr Emerg Care       Date:  1989-12       Impact factor: 1.454

8.  Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.

Authors:  Florian Strasser; Diana Luftner; Kurt Possinger; Gernot Ernst; Thomas Ruhstaller; Winfried Meissner; You-Dschun Ko; Martin Schnelle; Marcus Reif; Thomas Cerny
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

9.  Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.

Authors:  Jeremy R Johnson; Mary Burnell-Nugent; Dominique Lossignol; Elena Doina Ganae-Motan; Richard Potts; Marie T Fallon
Journal:  J Pain Symptom Manage       Date:  2009-11-05       Impact factor: 3.612

10.  Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users.

Authors:  Joshua A Lile; Thomas H Kelly; Richard J Charnigo; Audra L Stinchcomb; Lon R Hays
Journal:  J Clin Pharmacol       Date:  2013-06-10       Impact factor: 3.126
  10 in total
  2 in total

Review 1.  Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics.

Authors:  Gerhard Nahler
Journal:  Pharmaceut Med       Date:  2022-03-04

2.  Efficacy and safety of paediatric medicinal cannabis use: A scoping review.

Authors:  Colleen Pawliuk; Briana Chau; S Rod Rassekh; Terri McKellar; Harold Hal Siden
Journal:  Paediatr Child Health       Date:  2020-04-30       Impact factor: 2.253
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.